Close Menu

California Institute for Quantitative Biosciences

Scientists from the University of California, San Francisco, and the California Institute for Quantitative Biosciences, or QB3, have published a study demonstrating how picoinjection can be used to precisely and efficiently add reagents to individual digital PCR reaction volumes

The California Institute for Quantitative Biosciences will collaborate with Deloitte's life sciences consulting branch to develop its strategic plans for working with investors, companies, universities, and government.

QB3 plans to expand most likely at its East Bay space at UC Berkely. It also hopes to increase the number of firms receiving funding from its Mission Bay Capital seed venture fund.

The California Institute for Quantitative Biosciences hopes the Berkeley facility will enjoy the success of its QB3 [email protected] incubator, which has nurtured some 28 biotech startups in two sites since opening in 2006.

QB3 now has 18 tenants at its incubators within San Francisco's Mission Bay campus. It also said that an affiliate of Italian drug firm Zambon has invested in its first venture fund.

The California Institute for Quantitative Biosciences is looking for additional limited partners to help the firm fund new startups in the life sciences.

Mission Bay Capital is "expecting to make two to four investments a year over the next three or four years," a QB3 official told GWDN.

The California Institute for Quantitative Biosciences has filed documents with the SEC signaling its intention to raise $15 million to support spinouts.

The expansion, which will quadruple the amount of incubator space that QB3 currently operates, is designed to quench the growing thirst of life science startups for incubator space at Mission Bay.

Approximately one year after Pfizer and the California Institute for Quantitative Biosciences inked a three-year, $9.5 million drug-discovery pact, the alliance is now overseeing seven projects combining scientists from various Pfizer sites and QB3-affiliated researchers at UC-San Francisco.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.